Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Central Nervous System Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
52 drugs · 206 active trials
5 drugs · 33 active trials
5 drugs · 185 active trials
Outside the funnel: Phase not stated 1 · Withdrawn 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 22 minutes agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Nintedanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2011-01 |
| Perifosine | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2006-05 |
| Thalidomide | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2003-10 |
| Vandetanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | May 25, 2007 |
| Aflibercept | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2006-08 |
| Akt Inhibitor MK2206 | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2011-01 |
| Belinostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2006-03 |
| Bosutinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2009-09 |
| Cabazitaxel | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2013-04 |
| Ceritinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Feb 17, 2016 |
| Cixutumumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2009-01 |
| Crenolanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2011-07 |
| Dovitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Dec 20, 2012 |
| Fluorouracil | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2005-09 |
| Infigratinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Dec 9, 2013 |
| Pexidartinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Dec 3, 2011 |
| Romidepsin | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2002-09 |
| Tislelizumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Mar 24, 2021 |
| Trastuzumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | May 19, 2011 |
| Alectinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | May 7, 2018 |
| Aspirin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2008-11 |
| Binimetinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 29, 2019 |
| Birabresib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 29, 2014 |
| Copanlisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 23, 2018 |
| Dacomitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-04 |
| Encorafenib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 29, 2019 |
| Futuximab/Modotuximab Mixture | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Feb 1, 2016 |
| Glasdegib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 15, 2018 |
| Hydroxychloroquine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-05 |
| Imatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2006-02 |
| Lurbinectedin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | May 6, 2016 |
| Multikinase Inhibitor AEE788 | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-01 |
| Olaratumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-07 |
| Onartuzumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 29, 2012 |
| Onatasertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 20, 2010 |
| Pemigatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | May 20, 2022 |
| Ponatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 13, 2015 |
| Ramucirumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-07 |
| Rilotumumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-08 |
| Rovalpituzumab Tesirine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 23, 2016 |
| Sertraline | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2016-11 |
| Streptozocin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 1996-08 |
| Talazoparib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jan 1, 2021 |
| Tandutinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-01 |
| Tivozanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-06 |
| Trastuzumab Emtansine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 18, 2018 |
| Tremelimumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 1, 2016 |
| Vinorelbine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 2, 2015 |
| Azacitidine | Phase 1 | Phase 1 | 1 | 0 | 0 | 3 | 0 | — | — | Oct 27, 2014 |
| Sapanisertib | Phase 1 | Phase 1 | 1 | 0 | 0 | 2 | 0 | — | — | May 20, 2014 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.